Epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) are the current
recommended option for the first-line treatment of patients with EGFR-mutant non-small cell …

Gastric cancer is one of the most frequent malignancies worldwide. Despite improvements in
diagnosis and therapy, the overall prognosis remains poor. In the last decade, several anti …

Background The OPTIMAL study was the first study to compare efficacy and tolerability of the
epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI) erlotinib, versus …

ABSTRACT Introduction: Epidermal Growth Factor Receptor (EGFR)-dependent signaling
plays a crucial role in epithelial cancer biology, and dictated the development of several …

Rash and diarrhea are common side effects of tyrosine kinase inhibitor (TKI) therapy
administered to patients with non-small cell lung cancer (NSCLC). The polymorphisms of the …

We examined the benefits of the combination of anti-EGFR targeted treatment, cetuximab
(CTX) or nimotuzumab (NTZ) and concurrent platinum-based chemoradiotherapy (CCRT) …

Non-small cell lung cancer (NSCLC) accounts for 80–85% of all lung cancer which is the
leading cause of cancer death worldwide. Eighty percent of NSCLC patients exhibit high …

Purpose To retrospectively evaluate the clinical outcomes of radiofrequency (RF) ablation
for the treatment of unresectable adrenal metastasis. Materials and Methods The institutional …

Lung cancer is the leading cause of cancer death in both males and females in the US and
worldwide. Owing to advances in prevention, screening/early detection, and therapy, lung …

Platinum-based chemotherapeutic drugs are irreplaceable for the treatment of advanced
non-small cell lung cancer (NSCLC). However, acquired drug resistance has become a …